Healthcare >> Analyst Interviews >> November 15, 2010

An Eye On Value & Long-term Growth In Health Services – Dr. Alastair Mackay – Garp Research & Securities

Dr. ALASTAIR MACKAY, Ph.D., joined GARP Research & Securities in 2005. In 2007 and 2008, he garnered respectable rankings in The Wall Street Journal's "Best on the Street" annual survey of the sell side. As a researcher at Osiris Therapeutics (1996-2005), Dr. Mackay studied the growth and differentiation of human mesenchymal stem cells. Before that, he was a postdoctoral fellow at the Johns Hopkins University (1989-1995), where he used "reverse-genetics" to identify the function of INCENP, an essential protein component of chromosomes. Dr. Mackay earned his doctorate from the University of Vermont in 1989 by studying carcinogenesis in asbestos-induced mesotheliomas. Profile
TWST: What companies do you cover in the medical research universe?

Dr. Mackay: In implantable devices, I cover Edwards (EW) and Thoratec (THOR). In diagnostics, I cover Beckman Coulter (BEC),